Exploration of Targeted Anti-tumor Therapy (Aug 2022)

miRNA therapeutics in precision oncology: a natural premium to nurture

  • Chakresh Kumar Jain,
  • Poornima Srivastava,
  • Amit Kumar Pandey,
  • Nisha Singh,
  • R Suresh Kumar

DOI
https://doi.org/10.37349/etat.2022.00098
Journal volume & issue
Vol. 3, no. 4
pp. 511 – 532

Abstract

Read online

The dynamic spectrum of microRNA (miRNA) has grown significantly over the years with its identification and exploration in cancer therapeutics and is currently identified as an important resource for innovative strategies due to its functional behavior for gene regulation and modulation of complex biological networks. The progression of cancer is the consequence of uncontrolled, nonsynchronous procedural faults in the biological system. Diversified and variable cellular response of cancerous cells has always raised challenges in effective cancer therapy. miRNAs, a class of non-coding RNAs (ncRNAs), are the natural genetic gift, responsible to preserve the homeostasis of cell to nurture. The unprecedented significance of endogenous miRNAs has exhibited promising therapeutic potential in cancer therapeutics. Currently, miRNA mimic miR-34, and an antimiR aimed against miR-122 has entered the clinical trials for cancer treatments. This review, highlights the recent breakthroughs, challenges, clinical trials, and advanced delivery vehicles in the administration of miRNA therapies for precision oncology.

Keywords